Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306811 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT02306811 is a Phase 2 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 62 participants.
The verdict
NCT02306811, a Phase 2 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
Primary Objective: To assess the long-term safety of vatelizumab in MS patients Secondary Objective: To assess the long-term efficacy of vatelizumab
Interventions
- DRUG Vatelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306811
The ClinicalTrials.gov registry entry for NCT02306811 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vatelizumab is the first listed.
NCT02306811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306811 about?
NCT02306811 is a clinical study titled "Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839". Primary Objective: To assess the long-term safety of vatelizumab in MS patients Secondary Objective: To assess the long-term efficacy of vatelizumab
What is the current status of trial NCT02306811?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2015-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02306811?
The interventions under investigation include: Vatelizumab (DRUG).
Who is sponsoring clinical trial NCT02306811?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.